Analysts predict that Neos Therapeutics (NASDAQ:NEOS) will announce earnings per share of ($0.51) for the current quarter, Zacks reports. Zero analysts have made estimates for Neos Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.53). Neos Therapeutics reported earnings per share of ($0.87) during the same quarter last year, which would suggest a positive year-over-year growth rate of 41.4%. The business is expected to report its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Neos Therapeutics will report full-year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.86) to ($1.20). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.10) to $0.05. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Neos Therapeutics.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.12. The business had revenue of $7.79 million for the quarter, compared to analysts’ expectations of $9.30 million. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%.
Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in shares of Neos Therapeutics in the 3rd quarter worth $120,000. Paloma Partners Management Co purchased a new stake in shares of Neos Therapeutics in the 4th quarter worth $125,000. MetLife Investment Advisors LLC purchased a new stake in shares of Neos Therapeutics in the 4th quarter worth $134,000. New York State Common Retirement Fund increased its stake in Neos Therapeutics by 67.3% in the 3rd quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock worth $159,000 after buying an additional 7,000 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in Neos Therapeutics in the 4th quarter worth $179,000. Hedge funds and other institutional investors own 49.33% of the company’s stock.
NEOS stock opened at $8.50 on Friday. Neos Therapeutics has a 12-month low of $6.30 and a 12-month high of $13.15. The company has a debt-to-equity ratio of 7.47, a quick ratio of 1.84 and a current ratio of 2.20.
COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Neos Therapeutics (NEOS) Will Announce Earnings of -$0.51 Per Share” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2018/04/18/zacks-analysts-anticipate-neos-therapeutics-neos-will-announce-earnings-of-0-51-per-share.html.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.